| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Veterans | 29 | 2024 | 1742 | 2.730 |
Why?
|
| Hepatitis C, Chronic | 12 | 2018 | 472 | 1.970 |
Why?
|
| Liver Cirrhosis | 15 | 2018 | 1047 | 1.740 |
Why?
|
| Hepatitis C | 8 | 2018 | 548 | 1.170 |
Why?
|
| HIV Infections | 14 | 2024 | 2155 | 1.010 |
Why?
|
| Sarcoma, Kaposi | 3 | 2022 | 190 | 0.900 |
Why?
|
| Stress Disorders, Post-Traumatic | 4 | 2020 | 634 | 0.900 |
Why?
|
| Carcinoma, Hepatocellular | 8 | 2024 | 2191 | 0.860 |
Why?
|
| Liver Neoplasms | 10 | 2024 | 4839 | 0.800 |
Why?
|
| Glaucoma, Open-Angle | 2 | 2021 | 41 | 0.770 |
Why?
|
| Receptor for Advanced Glycation End Products | 2 | 2018 | 39 | 0.740 |
Why?
|
| Hepacivirus | 5 | 2017 | 423 | 0.700 |
Why?
|
| Liver Diseases | 4 | 2015 | 600 | 0.680 |
Why?
|
| Papillomavirus Infections | 3 | 2023 | 999 | 0.680 |
Why?
|
| Oropharyngeal Neoplasms | 3 | 2023 | 1162 | 0.660 |
Why?
|
| alpha-Fetoproteins | 3 | 2018 | 255 | 0.640 |
Why?
|
| United States Department of Veterans Affairs | 6 | 2024 | 664 | 0.620 |
Why?
|
| Gastrointestinal Microbiome | 7 | 2023 | 971 | 0.620 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2019 | 189 | 0.620 |
Why?
|
| Irritable Bowel Syndrome | 4 | 2024 | 211 | 0.610 |
Why?
|
| Parkinson Disease | 2 | 2020 | 696 | 0.600 |
Why?
|
| Adipokines | 1 | 2018 | 96 | 0.590 |
Why?
|
| Polymorphism, Genetic | 3 | 2015 | 1557 | 0.580 |
Why?
|
| Colon | 5 | 2021 | 684 | 0.560 |
Why?
|
| Algorithms | 5 | 2019 | 3906 | 0.550 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 357 | 0.500 |
Why?
|
| Persian Gulf Syndrome | 2 | 2024 | 15 | 0.470 |
Why?
|
| Middle Aged | 51 | 2024 | 90533 | 0.460 |
Why?
|
| Diet | 3 | 2019 | 1470 | 0.440 |
Why?
|
| Fatty Liver | 2 | 2012 | 248 | 0.440 |
Why?
|
| United States | 26 | 2024 | 15828 | 0.430 |
Why?
|
| Head and Neck Neoplasms | 3 | 2023 | 4148 | 0.420 |
Why?
|
| Body Fat Distribution | 1 | 2012 | 30 | 0.420 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2012 | 16 | 0.410 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2023 | 5604 | 0.410 |
Why?
|
| Finasteride | 1 | 2012 | 29 | 0.400 |
Why?
|
| Review Literature as Topic | 1 | 2012 | 81 | 0.400 |
Why?
|
| Risk | 5 | 2020 | 1930 | 0.400 |
Why?
|
| Peer Review, Research | 1 | 2012 | 66 | 0.400 |
Why?
|
| Intestinal Mucosa | 5 | 2023 | 1111 | 0.400 |
Why?
|
| Bibliometrics | 1 | 2012 | 64 | 0.400 |
Why?
|
| Vitamin D Deficiency | 1 | 2013 | 123 | 0.390 |
Why?
|
| Narcotics | 1 | 2012 | 126 | 0.390 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 271 | 0.390 |
Why?
|
| Risk Factors | 21 | 2024 | 17861 | 0.380 |
Why?
|
| Incidence | 12 | 2024 | 5825 | 0.380 |
Why?
|
| Electronic Health Records | 2 | 2019 | 854 | 0.370 |
Why?
|
| Diabetes Mellitus | 4 | 2023 | 1042 | 0.370 |
Why?
|
| Vitamin D | 1 | 2013 | 263 | 0.370 |
Why?
|
| Wnt Signaling Pathway | 1 | 2013 | 443 | 0.360 |
Why?
|
| Humans | 84 | 2024 | 270713 | 0.360 |
Why?
|
| Case-Control Studies | 9 | 2024 | 6233 | 0.360 |
Why?
|
| Adiposity | 1 | 2012 | 238 | 0.360 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 603 | 0.350 |
Why?
|
| Methadone | 1 | 2012 | 213 | 0.350 |
Why?
|
| Cross-Sectional Studies | 13 | 2022 | 4494 | 0.350 |
Why?
|
| Spouse Abuse | 1 | 2009 | 18 | 0.340 |
Why?
|
| Gastroenterology | 1 | 2012 | 202 | 0.340 |
Why?
|
| Postmenopause | 5 | 2018 | 374 | 0.340 |
Why?
|
| Sex Offenses | 1 | 2010 | 50 | 0.330 |
Why?
|
| Male | 47 | 2024 | 128479 | 0.330 |
Why?
|
| Barrett Esophagus | 4 | 2020 | 560 | 0.330 |
Why?
|
| Caffeine | 2 | 2023 | 95 | 0.320 |
Why?
|
| Feeding Behavior | 2 | 2015 | 812 | 0.320 |
Why?
|
| Bacteria | 4 | 2022 | 650 | 0.310 |
Why?
|
| Anti-HIV Agents | 2 | 2022 | 356 | 0.300 |
Why?
|
| Aggression | 1 | 2009 | 250 | 0.290 |
Why?
|
| Aged | 29 | 2024 | 73613 | 0.290 |
Why?
|
| Sex Factors | 5 | 2019 | 2180 | 0.280 |
Why?
|
| Motor Activity | 1 | 2010 | 711 | 0.270 |
Why?
|
| Prevalence | 8 | 2024 | 3395 | 0.270 |
Why?
|
| Glutathione Transferase | 1 | 2007 | 364 | 0.270 |
Why?
|
| Inflammation | 4 | 2020 | 2491 | 0.270 |
Why?
|
| Obesity | 4 | 2022 | 2895 | 0.270 |
Why?
|
| Testosterone | 1 | 2011 | 638 | 0.270 |
Why?
|
| Coffee | 3 | 2023 | 33 | 0.270 |
Why?
|
| Wounds and Injuries | 1 | 2010 | 424 | 0.270 |
Why?
|
| Female | 43 | 2024 | 148885 | 0.260 |
Why?
|
| Disease Progression | 3 | 2022 | 6881 | 0.250 |
Why?
|
| Esophageal Neoplasms | 5 | 2020 | 3241 | 0.250 |
Why?
|
| Substance-Related Disorders | 2 | 2009 | 546 | 0.250 |
Why?
|
| Adult | 25 | 2024 | 82041 | 0.240 |
Why?
|
| Biomarkers, Tumor | 2 | 2018 | 10726 | 0.240 |
Why?
|
| Surveys and Questionnaires | 8 | 2024 | 5923 | 0.220 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 5258 | 0.220 |
Why?
|
| Immunogenetics | 1 | 2023 | 18 | 0.220 |
Why?
|
| Logistic Models | 4 | 2024 | 3429 | 0.220 |
Why?
|
| Risk Assessment | 8 | 2024 | 6766 | 0.210 |
Why?
|
| Prospective Studies | 12 | 2021 | 13419 | 0.210 |
Why?
|
| Suppressor of Cytokine Signaling Proteins | 1 | 2023 | 62 | 0.210 |
Why?
|
| Trans Fatty Acids | 1 | 2022 | 10 | 0.210 |
Why?
|
| Age Factors | 5 | 2019 | 5441 | 0.210 |
Why?
|
| HIV | 2 | 2021 | 236 | 0.210 |
Why?
|
| RNA, Ribosomal, 16S | 5 | 2023 | 509 | 0.200 |
Why?
|
| Alcohol Drinking | 3 | 2020 | 599 | 0.200 |
Why?
|
| Penile Neoplasms | 1 | 2024 | 183 | 0.200 |
Why?
|
| Sleep | 2 | 2017 | 444 | 0.200 |
Why?
|
| Interleukins | 2 | 2015 | 340 | 0.190 |
Why?
|
| Hyperlipidemias | 1 | 2023 | 220 | 0.190 |
Why?
|
| Tooth Loss | 1 | 2020 | 4 | 0.180 |
Why?
|
| Antiviral Agents | 3 | 2017 | 1246 | 0.180 |
Why?
|
| Periodontal Diseases | 1 | 2020 | 14 | 0.180 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 3 | 2018 | 444 | 0.180 |
Why?
|
| Principal Component Analysis | 2 | 2018 | 221 | 0.180 |
Why?
|
| Calcium-Binding Proteins | 1 | 2023 | 542 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 367 | 0.180 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 207 | 0.170 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 2 | 2017 | 15 | 0.170 |
Why?
|
| Registries | 2 | 2019 | 2210 | 0.170 |
Why?
|
| Comorbidity | 4 | 2020 | 2393 | 0.170 |
Why?
|
| Odds Ratio | 3 | 2010 | 2299 | 0.170 |
Why?
|
| Patient Readmission | 2 | 2015 | 571 | 0.170 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2024 | 5777 | 0.170 |
Why?
|
| Geography | 1 | 2019 | 136 | 0.160 |
Why?
|
| Alphapapillomavirus | 1 | 2021 | 172 | 0.160 |
Why?
|
| Osteoarthritis, Knee | 1 | 2022 | 193 | 0.160 |
Why?
|
| Retrospective Studies | 13 | 2024 | 39959 | 0.160 |
Why?
|
| Health Services Administration | 1 | 2018 | 12 | 0.160 |
Why?
|
| Cohort Studies | 9 | 2024 | 9463 | 0.160 |
Why?
|
| Plasminogen Inactivators | 1 | 2018 | 8 | 0.160 |
Why?
|
| Gout | 1 | 2021 | 146 | 0.150 |
Why?
|
| HIV Protease Inhibitors | 1 | 2018 | 74 | 0.150 |
Why?
|
| Alanine Transaminase | 1 | 2018 | 235 | 0.150 |
Why?
|
| Diet, Fat-Restricted | 1 | 2018 | 52 | 0.150 |
Why?
|
| Adiponectin | 1 | 2018 | 142 | 0.140 |
Why?
|
| Burkitt Lymphoma | 1 | 2020 | 350 | 0.140 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 193 | 0.140 |
Why?
|
| Anus Neoplasms | 1 | 2021 | 414 | 0.140 |
Why?
|
| Receptors, Ghrelin | 1 | 2016 | 32 | 0.140 |
Why?
|
| Databases, Factual | 3 | 2020 | 2258 | 0.130 |
Why?
|
| Mexican Americans | 1 | 2018 | 330 | 0.130 |
Why?
|
| Ghrelin | 1 | 2016 | 69 | 0.130 |
Why?
|
| Leptin | 1 | 2018 | 304 | 0.130 |
Why?
|
| Nutritional Sciences | 1 | 2016 | 68 | 0.130 |
Why?
|
| Sensitivity and Specificity | 5 | 2019 | 5157 | 0.130 |
Why?
|
| Hypertension | 2 | 2023 | 1584 | 0.130 |
Why?
|
| Psychiatric Rehabilitation | 1 | 2015 | 8 | 0.130 |
Why?
|
| Alcohol Abstinence | 1 | 2015 | 17 | 0.130 |
Why?
|
| Activities of Daily Living | 2 | 2016 | 555 | 0.130 |
Why?
|
| Genome-Wide Association Study | 1 | 2024 | 2347 | 0.120 |
Why?
|
| Arthroplasty, Replacement | 1 | 2015 | 38 | 0.120 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2020 | 296 | 0.120 |
Why?
|
| Bias | 2 | 2013 | 210 | 0.120 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2023 | 1901 | 0.120 |
Why?
|
| Gulf War | 2 | 2024 | 8 | 0.120 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 6193 | 0.120 |
Why?
|
| Hospitals, Veterans | 2 | 2018 | 370 | 0.120 |
Why?
|
| Mortality | 1 | 2016 | 347 | 0.120 |
Why?
|
| Microbiota | 1 | 2020 | 545 | 0.120 |
Why?
|
| Health Education | 1 | 2016 | 302 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2016 | 1417 | 0.110 |
Why?
|
| Adenocarcinoma | 4 | 2020 | 7920 | 0.110 |
Why?
|
| ROC Curve | 1 | 2017 | 1250 | 0.110 |
Why?
|
| Severity of Illness Index | 6 | 2018 | 4394 | 0.110 |
Why?
|
| Young Adult | 4 | 2019 | 22243 | 0.110 |
Why?
|
| Elective Surgical Procedures | 1 | 2015 | 248 | 0.110 |
Why?
|
| Diet Records | 1 | 2013 | 80 | 0.110 |
Why?
|
| Colorectal Surgery | 1 | 2013 | 35 | 0.110 |
Why?
|
| Aged, 80 and over | 6 | 2020 | 31116 | 0.110 |
Why?
|
| Diabetes Complications | 1 | 2015 | 309 | 0.100 |
Why?
|
| Fructose | 1 | 2013 | 67 | 0.100 |
Why?
|
| Hepatitis | 1 | 2013 | 88 | 0.100 |
Why?
|
| Behavior Therapy | 1 | 2015 | 302 | 0.100 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2012 | 38 | 0.100 |
Why?
|
| Dietary Carbohydrates | 1 | 2013 | 128 | 0.100 |
Why?
|
| Disease Management | 1 | 2018 | 1092 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2021 | 2037 | 0.100 |
Why?
|
| Alcoholism | 1 | 2015 | 333 | 0.100 |
Why?
|
| Optical Imaging | 1 | 2013 | 158 | 0.100 |
Why?
|
| Primary Health Care | 1 | 2018 | 834 | 0.100 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 4317 | 0.100 |
Why?
|
| Neurofibrillary Tangles | 1 | 1991 | 28 | 0.100 |
Why?
|
| Endosonography | 1 | 2014 | 551 | 0.090 |
Why?
|
| Data Collection | 2 | 2010 | 602 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2024 | 4644 | 0.090 |
Why?
|
| Endemic Diseases | 1 | 2010 | 59 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 2219 | 0.090 |
Why?
|
| Vietnam Conflict | 1 | 2009 | 9 | 0.090 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 657 | 0.090 |
Why?
|
| Body Mass Index | 1 | 2018 | 2227 | 0.090 |
Why?
|
| Endoscopy | 1 | 2013 | 495 | 0.090 |
Why?
|
| Vietnam | 1 | 2009 | 64 | 0.090 |
Why?
|
| Predictive Value of Tests | 2 | 2015 | 4966 | 0.090 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 4992 | 0.080 |
Why?
|
| Iraq War, 2003-2011 | 1 | 2009 | 117 | 0.080 |
Why?
|
| Afghan Campaign 2001- | 1 | 2009 | 122 | 0.080 |
Why?
|
| Viral Load | 1 | 2011 | 481 | 0.080 |
Why?
|
| Hepatitis B | 2 | 2010 | 273 | 0.080 |
Why?
|
| Mass Screening | 1 | 2018 | 1547 | 0.080 |
Why?
|
| Neoplasms | 4 | 2021 | 15949 | 0.080 |
Why?
|
| Proportional Hazards Models | 4 | 2019 | 5099 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1337 | 0.080 |
Why?
|
| Colorectal Neoplasms | 2 | 2016 | 3707 | 0.080 |
Why?
|
| Papillomaviridae | 2 | 2022 | 636 | 0.080 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2007 | 316 | 0.070 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2007 | 67 | 0.070 |
Why?
|
| Dyspepsia | 1 | 2008 | 112 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2013 | 1186 | 0.070 |
Why?
|
| Unsafe Sex | 1 | 2007 | 21 | 0.070 |
Why?
|
| Military Personnel | 1 | 2009 | 234 | 0.070 |
Why?
|
| Feces | 2 | 2021 | 851 | 0.070 |
Why?
|
| Time Factors | 4 | 2017 | 12978 | 0.070 |
Why?
|
| Biomarkers | 3 | 2018 | 5048 | 0.070 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 2339 | 0.070 |
Why?
|
| Methamphetamine | 1 | 2007 | 61 | 0.070 |
Why?
|
| Central Nervous System Stimulants | 2 | 2007 | 191 | 0.070 |
Why?
|
| Confidence Intervals | 1 | 2007 | 747 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2010 | 567 | 0.070 |
Why?
|
| Quality of Life | 3 | 2009 | 4810 | 0.070 |
Why?
|
| Disability Evaluation | 1 | 2007 | 242 | 0.060 |
Why?
|
| Medical Records | 1 | 2007 | 441 | 0.060 |
Why?
|
| Coinfection | 2 | 2017 | 198 | 0.060 |
Why?
|
| Isoenzymes | 1 | 2007 | 644 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2013 | 2658 | 0.060 |
Why?
|
| Adolescent Behavior | 1 | 2007 | 237 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 402 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2007 | 1307 | 0.060 |
Why?
|
| Genotype | 2 | 2013 | 4248 | 0.060 |
Why?
|
| Alzheimer Disease | 1 | 1991 | 821 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2007 | 907 | 0.060 |
Why?
|
| Needlestick Injuries | 1 | 2003 | 7 | 0.060 |
Why?
|
| Protective Devices | 1 | 2003 | 20 | 0.060 |
Why?
|
| Aging | 1 | 1991 | 1531 | 0.050 |
Why?
|
| North America | 1 | 2024 | 337 | 0.050 |
Why?
|
| Circadian Rhythm | 2 | 2017 | 331 | 0.050 |
Why?
|
| Gastrointestinal Diseases | 1 | 2008 | 616 | 0.050 |
Why?
|
| Texas | 2 | 2012 | 6446 | 0.050 |
Why?
|
| Cardiomyopathies | 1 | 2008 | 548 | 0.050 |
Why?
|
| Interferons | 2 | 2015 | 297 | 0.050 |
Why?
|
| Nurses | 1 | 2003 | 85 | 0.050 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 2022 | 55 | 0.050 |
Why?
|
| Occupational Diseases | 1 | 2003 | 131 | 0.050 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2022 | 76 | 0.050 |
Why?
|
| Adenosine Deaminase | 1 | 2022 | 113 | 0.050 |
Why?
|
| Verrucomicrobia | 1 | 2021 | 26 | 0.050 |
Why?
|
| Genetic Loci | 1 | 2024 | 501 | 0.050 |
Why?
|
| Regression Analysis | 2 | 2019 | 1562 | 0.050 |
Why?
|
| Catheterization, Peripheral | 1 | 2003 | 153 | 0.050 |
Why?
|
| Stress, Psychological | 1 | 2008 | 1038 | 0.050 |
Why?
|
| Knee Joint | 1 | 2022 | 168 | 0.050 |
Why?
|
| Oral Health | 1 | 2020 | 21 | 0.050 |
Why?
|
| Bacterial Load | 1 | 2020 | 45 | 0.050 |
Why?
|
| Intraocular Pressure | 1 | 2021 | 156 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2022 | 244 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2022 | 340 | 0.040 |
Why?
|
| Research Design | 1 | 2008 | 1562 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 825 | 0.040 |
Why?
|
| Sample Size | 2 | 2013 | 212 | 0.040 |
Why?
|
| Treatment Outcome | 6 | 2021 | 33847 | 0.040 |
Why?
|
| Heart Failure | 2 | 2016 | 2330 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2022 | 437 | 0.040 |
Why?
|
| Food Analysis | 1 | 2019 | 28 | 0.040 |
Why?
|
| Weight Gain | 1 | 2022 | 465 | 0.040 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2022 | 659 | 0.040 |
Why?
|
| Liver Cirrhosis, Alcoholic | 1 | 2018 | 46 | 0.040 |
Why?
|
| Smoking | 2 | 2019 | 2549 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2019 | 98 | 0.040 |
Why?
|
| Edible Grain | 1 | 2018 | 50 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2019 | 315 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2018 | 122 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2013 | 5674 | 0.040 |
Why?
|
| Platelet Count | 1 | 2018 | 488 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 103 | 0.040 |
Why?
|
| Body Weight | 1 | 2022 | 1287 | 0.040 |
Why?
|
| Prognosis | 1 | 2015 | 22528 | 0.040 |
Why?
|
| Radiography | 1 | 2022 | 1994 | 0.040 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2019 | 165 | 0.040 |
Why?
|
| Hepatitis B, Chronic | 1 | 2018 | 139 | 0.040 |
Why?
|
| Sleep Apnea Syndromes | 1 | 1998 | 87 | 0.040 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 604 | 0.040 |
Why?
|
| Life Style | 1 | 2020 | 617 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2003 | 899 | 0.030 |
Why?
|
| SEER Program | 1 | 2020 | 1052 | 0.030 |
Why?
|
| Women's Health | 1 | 2017 | 191 | 0.030 |
Why?
|
| Schizophrenia | 1 | 1979 | 317 | 0.030 |
Why?
|
| Fruit | 1 | 2018 | 303 | 0.030 |
Why?
|
| Paris | 1 | 2015 | 11 | 0.030 |
Why?
|
| Vegetables | 1 | 2018 | 331 | 0.030 |
Why?
|
| Liver Function Tests | 1 | 2015 | 184 | 0.030 |
Why?
|
| Survival Rate | 2 | 2020 | 12530 | 0.030 |
Why?
|
| Phenotype | 2 | 2022 | 6502 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 1979 | 429 | 0.030 |
Why?
|
| Self Report | 1 | 2018 | 794 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2016 | 350 | 0.030 |
Why?
|
| End Stage Liver Disease | 1 | 2016 | 190 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 7916 | 0.030 |
Why?
|
| Contraindications | 1 | 2013 | 153 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 781 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 626 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2018 | 1060 | 0.030 |
Why?
|
| Computational Biology | 1 | 2019 | 1295 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 2560 | 0.030 |
Why?
|
| Biopsy | 1 | 2020 | 3490 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2013 | 205 | 0.030 |
Why?
|
| Adolescent | 2 | 2010 | 32689 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2018 | 1931 | 0.020 |
Why?
|
| Amyloid | 1 | 1991 | 91 | 0.020 |
Why?
|
| Asia, Southeastern | 1 | 2010 | 24 | 0.020 |
Why?
|
| Surgery, Plastic | 1 | 1993 | 153 | 0.020 |
Why?
|
| Hormone Replacement Therapy | 1 | 2013 | 215 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 1344 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 1246 | 0.020 |
Why?
|
| Africa South of the Sahara | 1 | 2010 | 111 | 0.020 |
Why?
|
| Antidepressive Agents | 2 | 1979 | 334 | 0.020 |
Why?
|
| Helicobacter pylori | 1 | 2019 | 1411 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2016 | 885 | 0.020 |
Why?
|
| Ambulatory Care | 2 | 2007 | 592 | 0.020 |
Why?
|
| Overweight | 1 | 2012 | 484 | 0.020 |
Why?
|
| Autonomic Agents | 1 | 2008 | 2 | 0.020 |
Why?
|
| Selenoproteins | 1 | 2008 | 15 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 15275 | 0.020 |
Why?
|
| Length of Stay | 1 | 2015 | 1997 | 0.020 |
Why?
|
| Ubiquinone | 1 | 2008 | 30 | 0.020 |
Why?
|
| Brain Mapping | 1 | 1991 | 624 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2008 | 432 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2008 | 161 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 1127 | 0.020 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2016 | 1065 | 0.020 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 171 | 0.020 |
Why?
|
| Ventricular Remodeling | 1 | 2008 | 186 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2012 | 721 | 0.020 |
Why?
|
| Animals | 5 | 2022 | 61357 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2008 | 229 | 0.020 |
Why?
|
| Streptomyces griseus | 1 | 1975 | 1 | 0.020 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2008 | 235 | 0.020 |
Why?
|
| Hexosaminidases | 1 | 1975 | 10 | 0.020 |
Why?
|
| Receptors, Adrenergic | 1 | 1976 | 53 | 0.020 |
Why?
|
| Acetylglucosaminidase | 1 | 1975 | 19 | 0.020 |
Why?
|
| Biogenic Amines | 1 | 1975 | 22 | 0.020 |
Why?
|
| Digitoxin | 1 | 1975 | 11 | 0.020 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 1975 | 30 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2007 | 185 | 0.020 |
Why?
|
| Patient Selection | 1 | 2013 | 2029 | 0.020 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 2454 | 0.020 |
Why?
|
| Hippocampus | 1 | 1991 | 926 | 0.020 |
Why?
|
| Microsomes, Liver | 1 | 1975 | 116 | 0.020 |
Why?
|
| Global Health | 1 | 2010 | 672 | 0.020 |
Why?
|
| Stroke | 1 | 2013 | 1061 | 0.020 |
Why?
|
| Antioxidants | 1 | 2008 | 519 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 453 | 0.010 |
Why?
|
| Dopamine | 1 | 1975 | 334 | 0.010 |
Why?
|
| Pedigree | 1 | 2008 | 2040 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2008 | 863 | 0.010 |
Why?
|
| Hospitals, Urban | 1 | 2003 | 99 | 0.010 |
Why?
|
| Streptococcus pneumoniae | 1 | 1975 | 405 | 0.010 |
Why?
|
| Time | 1 | 2003 | 182 | 0.010 |
Why?
|
| Inservice Training | 1 | 2003 | 73 | 0.010 |
Why?
|
| Hospitals, Teaching | 1 | 2003 | 123 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 7787 | 0.010 |
Why?
|
| Organizational Culture | 1 | 2003 | 115 | 0.010 |
Why?
|
| Myocardium | 1 | 2008 | 1180 | 0.010 |
Why?
|
| Patient Discharge | 1 | 2007 | 699 | 0.010 |
Why?
|
| Internship and Residency | 1 | 1993 | 1442 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 1587 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 1991 | 7648 | 0.010 |
Why?
|
| Convulsive Therapy | 1 | 1979 | 1 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 14033 | 0.010 |
Why?
|
| Cytokines | 1 | 2008 | 2803 | 0.010 |
Why?
|
| In Vitro Techniques | 3 | 1975 | 1696 | 0.010 |
Why?
|
| Social Adjustment | 1 | 1979 | 113 | 0.010 |
Why?
|
| Schizophrenic Psychology | 1 | 1979 | 82 | 0.010 |
Why?
|
| Electroconvulsive Therapy | 1 | 1979 | 66 | 0.010 |
Why?
|
| Health Status Indicators | 1 | 1998 | 230 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2007 | 3841 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 1998 | 566 | 0.010 |
Why?
|
| NADP | 2 | 1975 | 88 | 0.010 |
Why?
|
| Syndrome | 1 | 1979 | 1409 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2003 | 1225 | 0.010 |
Why?
|
| Bipolar Disorder | 1 | 1979 | 361 | 0.010 |
Why?
|
| Structure-Activity Relationship | 2 | 1976 | 975 | 0.010 |
Why?
|
| Kinetics | 2 | 1975 | 2206 | 0.010 |
Why?
|
| Pilot Projects | 1 | 1998 | 2856 | 0.010 |
Why?
|
| Rats | 2 | 1975 | 6397 | 0.000 |
Why?
|
| Depression, Chemical | 1 | 1975 | 56 | 0.000 |
Why?
|
| Digitoxigenin | 1 | 1975 | 6 | 0.000 |
Why?
|
| Homovanillic Acid | 1 | 1975 | 27 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1976 | 327 | 0.000 |
Why?
|
| Chromatography, Thin Layer | 1 | 1975 | 69 | 0.000 |
Why?
|
| Hydroxylation | 1 | 1975 | 58 | 0.000 |
Why?
|
| Fucose | 1 | 1975 | 58 | 0.000 |
Why?
|
| Propranolol | 1 | 1976 | 151 | 0.000 |
Why?
|
| Oligosaccharides | 1 | 1975 | 112 | 0.000 |
Why?
|
| Sheep | 1 | 1975 | 270 | 0.000 |
Why?
|
| Epinephrine | 1 | 1976 | 249 | 0.000 |
Why?
|
| Species Specificity | 1 | 1975 | 783 | 0.000 |
Why?
|
| Brain | 2 | 1975 | 4202 | 0.000 |
Why?
|
| Binding Sites | 1 | 1976 | 2249 | 0.000 |
Why?
|
| Protein Binding | 1 | 1976 | 3472 | 0.000 |
Why?
|
| Pyrimidines | 1 | 1975 | 3671 | 0.000 |
Why?
|